Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. - Wikidata - awgldk - TriplyDB

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

http://www.wikidata.org/entity/Q42455896

about

Medication-induced osteoporosis: screening and treatment strategies Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.Optimal bone health management strategies in patients with prostate cancer Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.Prostate cancer and osteoporosis.Prostate cancer: Bone density testing--essential or extraneous?A retrospective study of alendronate for the treatment of ankylosing spondylitis.Q57133506

P2860

Q34389358-C5EB92DC-7821-45A9-A3D7-BD86D2198B3C Q35022212-3210606D-413D-4202-B4C2-F1A0EF1808EC Q35206815-4BF67730-EF81-4551-88C1-A100931A1CB1 Q35865726-D2E5E6A4-6EB6-46E6-863A-7FCA1534FDDE Q37080734-3FE7C369-7824-42DE-B27F-23B32EB6C6B3 Q42214667-E3624C0E-FDDE-4E62-B1BF-91FE67C1975F Q45760007-CD24898B-893C-4A31-B5A7-82BEEB7C2231 Q46178186-E83240AD-778A-4A08-8BA3-B853AC984E39 Q55098638-4B7F5F8C-F7CC-49C6-9F2F-846B78E98E76 Q57133506-D9EC6499-C4CC-4020-88F2-07A4AA1D77AF

P2860

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

http://www.wikidata.org/entity/Q42455896

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Alendronate decreases the frac ...... re osteopenia or osteoporosis.

@en

Alendronate decreases the frac ...... re osteopenia or osteoporosis.

@nl

type

label

Alendronate decreases the frac ...... re osteopenia or osteoporosis.

@en

Alendronate decreases the frac ...... re osteopenia or osteoporosis.

@nl

prefLabel

Alendronate decreases the frac ...... re osteopenia or osteoporosis.

@en

Alendronate decreases the frac ...... re osteopenia or osteoporosis.

@nl

P1433

Q42455896-33D1F143-8422-483A-A515-06A3B7821CC4

P1476

Q42455896-E1ECF4FA-933C-4418-9D70-6F21A7FC20DA

P2093

Q42455896-0CF8F41B-209C-4D71-8842-E1080ACD4877

Q42455896-364507E0-C13C-47D9-AFD7-37DE1FDFC0C7

Q42455896-7399E40C-BCFC-48DC-BDEE-A56833C9877C

Q42455896-AD08C94B-E1EE-4780-8A91-0A8D6AF946C8

Q42455896-FCBB7530-DBAD-4AAF-95B3-8141B9C45F68

Q42455896-FD3A8B85-0430-4DA4-8FDF-A073A8B2457D

P2860

Q42455896-0B76D203-A038-4B69-AFD2-F0CAF6A68186

Q42455896-4C0CC954-CFB4-4362-809A-91F3306C2AB7

Q42455896-900C6B5B-4FAB-4DF2-B7FE-528B443E0A1C

Q42455896-D238F510-563B-4993-92DD-018E110FC82D

Q42455896-E317304A-F3D0-474E-ADFD-62D5E4F8EDCB

Q42455896-FDA0B56A-D075-4895-B07B-0915D166D275

P304

Q42455896-4416FBD2-87E6-4C69-8F7D-62C69099CAD5

P31

Q42455896-5AA7D9F9-BD1A-493F-90D2-FAB0B29A110C

P356

Q42455896-AA1E8AF6-84A7-47E4-BC9C-DC6A09E8C89D

P433

Q42455896-ED09DB5F-9F9C-4E2F-9F93-2613613A5FF0

P478

Q42455896-6B53D15F-B4BD-43B9-8917-A5197D6B1F99

P50

Q42455896-B509B99F-E2AA-45BF-BE31-038995CB23AF

Q42455896-E3A17427-9354-4376-BC58-C0A6A002833D

Q42455896-F0E23510-2F0C-4C54-A912-6D9ED0CC60FB

P577

Q42455896-A55BA685-FFE1-4A63-9A10-D8EF2688DA18

P698

Q42455896-4EFA3543-3F49-4B5E-8A34-4C40B35B7181

P921

Q42455896-7AFB467E-C656-49B8-95D5-B12B87241D73

P356

J.1464-410X.2009.08622.X

P1433

BJU International

P1476

Alendronate decreases the frac ...... ere osteopenia or osteoporosis

@en

P2093

Carles Raventós

http://www.w3.org/2001/XMLSchema#string

Carles Salvador

http://www.w3.org/2001/XMLSchema#string

Enrique Trilla

http://www.w3.org/2001/XMLSchema#string

Jacques Planas

http://www.w3.org/2001/XMLSchema#string

Jose Placer

http://www.w3.org/2001/XMLSchema#string

Juan Morote

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Management of bone loss in men with prostate cancer.

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Alendronate for the Treatment of Osteoporosis in Men

P304

1637-1640

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1464-410X.2009.08622.X

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Lluís Cecchini

P577

2009-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19549260

http://www.w3.org/2001/XMLSchema#string

P921